New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
09:16 EDTFTNT, JNJ, LOGI, TRIP, SKX, DNKN, ONVO, SRPT, VDSI, CAT, F, UA, QCOM, ANGI, GM, FBOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Facebook (FB), up 7.6%... Ford (F), up 1.4%... Skechers (SKX), up 8%... Under Armour (UA), up 8.5%... VASCO (VDSI), up 16.6%... Logitech (LOGI), up 14.4%... Fortinet (FTNT), up 9%. ALSO HIGHER: Organovo (ONVO), up 19.6% after entering a 3D bio-printed tissue agreement with a unit of J&J (JNJ). DOWN AFTER EARNINGS: General Motors (GM), down 2.4%... Dunkin' Brands (DNKN), down 7.8%... TripAdvisor (TRIP), down 9.7%... Qualcomm (QCOM), down 5.5%... Caterpillar (CAT), down 2.8%. ALSO LOWER: Angie's List (ANGI), down 18% after Q2 report last night, at least seven downgrades of stock this morning... Sarepta (SRPT), down 6.3% after terminating Chief Scientific Officer Arthur Krieg.
News For FB;GM;F;ONVO;ANGI;CAT;DNKN;QCOM;VDSI;SKX;UA;SRPT;TRIP;JNJ;FTNT;LOGI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
December 11, 2014
07:49 EDTGMThe New York Times to hold a conference
Subscribe for More Information
06:32 EDTQCOMGlobalfoundries hope to win orders from Qualcomm and Apple, DigiTimes reports
Subscribe for More Information
06:06 EDTQCOMQualcomm cutting 600 jobs worldwide, CNet reports
A Qualcomm spokesperson has confirmed that the company is planning to cut 600 jobs globally, with around half the cuts coming in California, CNet reports. The spokesperson notes that the layoffs are not related to ongoing investigations in the U.S., China and the EU, commenting that the layoffs are "focused on specific projects and programs and reflects current business priorities." Reference Link
December 10, 2014
11:12 EDTFBInstagram announces service now has over 300M users
Subscribe for More Information
09:36 EDTFBActive equity options trading
Subscribe for More Information
08:09 EDTFBFacebook management to meet with UBS
Subscribe for More Information
December 9, 2014
16:00 EDTFBOptions Update; December 9, 2014
Subscribe for More Information
12:48 EDTFBFacebook volatility at low end of historic range
Subscribe for More Information
10:07 EDTFTNTFortinet may receive buyout from Wipro, says AsianSweeper
Fortinet (FTNT) may receive a buyout from Wipro (WIT), AsianSweeper says. Wipro is looking to strengthen the market share in security solutions and Fortinet, the current revenue leader in unified threat management is a perfect fit, as two companies already have existing synergies in certain areas. Reference Link
09:17 EDTFTeleTech to expand in China through Percepta joint venture
TeleTech Holdings (TTEC) announced plans to expand in China through Percepta, a global joint venture with Ford Motor (F). Providing service and support through all stages of the customer lifecycle, Percepta operates customer contact centers on five continents specifically for the automotive industry.
07:37 EDTFUBS to hold a conference
Subscribe for More Information
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
11:10 EDTGM, FVolkswagen sees challenging developments continuing for rest of year
Volkswagen (VLKAY) said, “The challenging developments on markets worldwide – above all in Eastern Europe and South America – will continue for the remainder of this year. The Volkswagen Passenger Cars brand handled these challenges successfully during the course of the year, but was not entirely immune to their impact.” Other publicly traded companies in the passenger automotive space include Fiat Chrysler (FCAU), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), and Toyota (TM).
08:07 EDTFFord management to meet with UBS
Meeting to be held in Boston on December 8 hosted by UBS.
07:31 EDTQCOMQualcomm announces collabration with vitaphone e-health solutions
Subscribe for More Information
07:28 EDTFTNTFBN Securities to hold a bus tour
Subscribe for More Information
06:42 EDTDNKNDunkin' Brands coverage resumed with a Neutral at Goldman
Target $47.
December 7, 2014
14:54 EDTJNJIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use